These data clearly demonstrated the effect of the BMP receptor inhibitor LDN‐212854 on the inhibition of HCC tumor growth via suppressing BMP9‐ID1 signaling, which promotes EpCAM+ CSC properties, suggesting that targeting BMP9‐ID1 signaling could be a promising therapeutic option for HCC patients. This evidence concerns the gene ID1 and neoplasm.